Why is "Multiple myeloma" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-07-20 08:21:43
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Multiple_myeloma entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-07-20 and was most recently seen on 2026-07-20.
Wikipedia Overview
Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. Often, no symptoms are noticed initially. As it progresses, bone pain, anemia, renal insufficiency, and infections may occur. Complications may include hypercalcemia and amyloidosis.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Individualizing CAR T-Cell Therapy vs Bispecific Antibodies in Relapsed Multiple Myeloma - CancerNetwork
-
DEX: OsteoDex achieved strong safety and efficacy in multiple myeloma; liquidity secured through 2028 - TradingView
-
Nicholas Richardson: FDA Approves Iberdomide for Multiple Myeloma - Oncodaily
-
Individualized Treatment and Sequencing in Multiple Myeloma - OncLive
-
Evolving Multiple Myeloma Treatment Roadmap for Oncology Nurses - Cancer Nursing Today
-
Protein degrader approval offers hope to relapsed multiple myeloma patients - Chemistry World
-
HaemaLogiX Doses First Patient in Phase 1 Trial of Kappa-Targeted CAR-T Therapy KMCAR for Multiple Myeloma - BioPharm International
-
Introduction and Overview of CELMoDs in Multiple Myeloma - CancerNetwork
-
Treatment Duration and Emerging Strategies in Multiple Myeloma - OncLive
-
How Will Iberdomide’s Approval and Other CELMoDs Impact Multiple Myeloma? - CancerNetwork
-
Relapsed/Refractory Multiple Myeloma: Multidisciplinary Care and Caregiver Support - OncLive
-
CELMoD Mechanism and Differentiation From IMiDs in Multiple Myeloma - CancerNetwork
-
Relapsed/Refractory Multiple Myeloma: Setting Expectations After CAR T-Cell Therapy - OncLive
-
Where Do CELMoDs Fit With CAR T Cells and Bispecifics in Multiple Myeloma? - CancerNetwork
-
CELMoD Wins “Landmark Approval” in Relapsed/Refractory Multiple Myeloma - CancerNetwork
-
Debate: CAR-T Cell Therapy Versus BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma - CancerNetwork
-
Evolving Treatment Goals in Relapsed/Refractory Multiple Myeloma - CancerNetwork
-
Debate: Class Effect Versus Meaningful Differences Among BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma - CancerNetwork
-
Preparing for Advanced Therapy in Relapsed/Refractory Multiple Myeloma - CancerNetwork
-
Evolving Treatment Strategies in Relapsed/Refractory Multiple Myeloma - CancerNetwork
-
Behind the relentless pursuit of multiple myeloma cures - Johnson & Johnson
-
Understanding the Relapsed/Refractory Multiple Myeloma Journey - CancerNetwork
-
MAJESTEC-3 Evaluates Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma - CancerNetwork
-
One of “The Best Opportunities” for Long-Term Remission in Multiple Myeloma - CancerNetwork
-
FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class - STAT
-
FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma - The ASCO Post
-
Where Will Cell and Gene Therapy Go Next in Multiple Myeloma? - CancerNetwork
-
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis - Nature
-
Teclistamab Improves Progression-Free and Overall Survival in Previously Treated Multiple Myeloma - The ASCO Post
-
Teclistamab Improves Outcomes in Relapsed Multiple Myeloma - University of Miami
-
New therapeutic target expands options for multiple myeloma - Penn Medicine
-
The Emotional Impact of Relapsed/Refractory Multiple Myeloma - CancerNetwork
-
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial - Nature
-
Mayo Clinic-led study finds no improvement in overall survival from longer multiple myeloma maintenance therapy - Mayo Clinic News Network
-
Longitudinal Data Shapes Our Understanding of High-Risk Multiple Myeloma - Targeted Oncology
-
Johnson & Johnson’s multiple myeloma treatment secures EC approval - Pharmaceutical Technology
-
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse - Bristol Myers Squibb
-
FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma - Targeted Oncology
-
The New Era of Multiple Myeloma Care: How Immunotherapy is Redefining What’s Possible - AdventHealth
-
First patient dosed in Australian KOALA CAR-T trial for multiple myeloma - BioSpectrum Asia
-
BMS welcomes new multiple myeloma drug as generics batter current portfolio - BioSpace
-
Evolving Treatment Goals in Multiple Myeloma - OncLive
-
What Makes an Optimal CAR T-Cell Therapy Candidate in Multiple Myeloma - CancerNetwork
-
Improving how multiple myeloma is understood and treated - Mayo Clinic News Network
-
Striving for a cure for multiple myeloma: What HCPs need to know - Johnson & Johnson
-
ASCO 2026: Multiple Myeloma Studies Highlight Advances Across the Field - The ASCO Post
-
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial - Nature
-
FDA Approves Iberdomide Combo in Relapsed/Refractory Multiple Myeloma - CancerNetwork
-
Expanding Community Access to CAR T, Bispecific Therapies in Multiple Myeloma: Peter Forsberg, MD - The American Journal of Managed Care
-
Smoldering multiple myeloma in transition: redefining early myeloma in the modern era - Nature
-
Multiple Myeloma in 2026: Comprehensive Clinical Update - Oncodaily
-
EHA 2026: Dr Rahul Banerjee Discusses New Options in Multiple Myeloma (Video) - Cancer Therapy Advisor
-
New research redefines functional high-risk multiple myeloma in era of modern therapies - The University of Alabama at Birmingham
-
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial - Nature
-
Multiple Myeloma Back Pain: A Red Flag For Spinal Cord Compression - Cancer Nursing Today
-
Multiple Myeloma: Diagnosis and Treatment - American Academy Of Family Physicians | AAFP
-
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy - ASCO Publications
-
Multiple Myeloma Trial Explores Immunotheraphy Option - Froedtert & MCW
-
Smoldering Multiple Myeloma: From Clinical to Immunogenomic Risk Stratification and Therapeutic Implications of Early Intervention - ASCO Publications
-
Is a Functional Cure for Multiple Myeloma Within Reach? - Cure Today
-
Subcutaneous Sarclisa Escena Receives FDA Nod for Multiple Myeloma - Cancer Therapy Advisor
-
Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly - Nature
-
Teclistamab Combos Improve PFS, OS in Relapsed/Refractory Multiple Myeloma - CancerNetwork
-
FDA Approves Subcutaneous Isatuximab for Multiple Myeloma Indications - Oncology News Central
-
Relapsed/Refractory Multiple Myeloma: Recognizing and Managing Neurologic Events With GPRC5D-Directed Therapy - CancerNetwork
-
KMCAR myeloma CAR T-cell therapy safely doses first trial patient - Rare Cancer News
-
How Are CELMoDs Reshaping Treatment in Multiple Myeloma? - CancerNetwork
-
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial - Nature
-
Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma - Nature
-
Seven Years of Treatment for Multiple Myeloma, Endless Opportunity - Dana-Farber Cancer Institute
-
High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity - The ASCO Post
-
Machine Learning Model Outperforms Standard Risk Tools for Multiple Myeloma - Cleveland Clinic
-
Relapsed/Refractory Multiple Myeloma: Rationale and Design of the MonumenTAL-3 Study - CancerNetwork
-
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium | Blood Cancer Journal - Nature
-
Established cancer drug gives multiple myeloma immunotherapy new lease of life - Oncology Central
-
What Comes Next: Taking on Unanswered Questions in Multiple Myeloma - The American Journal of Managed Care
-
New Considerations Arise in Sequencing After Second Relapse in Multiple Myeloma - Targeted Oncology
-
Immune ecotypes may explain multiple myeloma outcomes missed by disease staging - UT MD Anderson
-
Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific Antibody - The ASCO Post
-
Teclistamab Outperforms Standard Therapy in Relapsed Multiple Myeloma - Inside Precision Medicine
-
FDA Approves Subcutaneous Isatuximab for Multiple Myeloma - Targeted Oncology
-
Teclistamab (Tecvayli) Improves Survival in Relapsed Multiple Myeloma - Oncology News Central
-
Why Collaborative Care Is Changing What It Means to Live With Multiple Myeloma - University of Miami
-
Multiple Myeloma: Shedding Light on a Rare but Complex Blood Cancer - Pfizer
-
Defining Functional High-Risk Multiple Myeloma in the Era of Quadruplet Therapy and Autologous Stem Cell Transplant - The ASCO Post
-
How CELMoDs’ Milder GI AEs May Reduce Discontinuation Rates in Multiple Myeloma - CancerNetwork
-
Enhanced dynamic risk stratification of smoldering multiple myeloma - Nature
-
Teclistamab in Previously Treated Multiple Myeloma - The ASCO Post
-
Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT - Nature
-
Charting Progress, Changing Outcomes: The Evolution of Multiple Myeloma Care - Sanofi
-
Arlo-Cel Shows Promise in Early-Line Relapsed Multiple Myeloma - Targeted Oncology
-
New therapeutic target expands options for multiple myeloma - Penn Today
-
Defining cure for multiple myeloma: Lu Anna’s story - Roswell Park Comprehensive Cancer Center
-
Why Earlier CAR-T Conversations Matter in Multiple Myeloma: Perspectives from a Patient and Community Oncologist - Fierce Healthcare
-
Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard? - CancerNetwork
-
Teclistamab Shows Promise in High-Risk Smoldering Multiple Myeloma - Oncology News Central
-
CAR-T Moves to the Front Line: Rethinking the Multiple Myeloma Sequence - CancerNetwork
-
Subcutaneous Isatuximab Approval Expands Options in Multiple Myeloma - CancerNetwork
-
Teclistamab Extends Survival, Deepens Remissions in Relapsed Multiple Myeloma - Cancer Health
-
Cevostamab May Fill Gap in Multiple Myeloma Armamentarium - CancerNetwork
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.